OOIR: Observatory of International Research

Papers

(The H4-Index of Molecular Cancer is 89. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives	965
Circular RNA: metabolism, functions and interactions with proteins	657
Combination strategies with PD-1/PD-L1 blockade: current advances and future directions	561
Ferroptosis in cancer therapy: a novel approach to reversing drug resistance	536
mRNA vaccine for cancer immunotherapy	532
The cancer metabolic reprogramming and immune response	522
Targeting TGF-β signal transduction for fibrosis and cancer therapy	385
Glioma targeted therapy: insight into future of molecular approaches	372
Exosomes as a new frontier of cancer liquid biopsy	368
Wnt signaling in colorectal cancer: pathogenic role and therapeutic target	330
Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments	323
The role of m6A RNA methylation in cancer metabolism	303
Targeting AURKA in Cancer: molecular mechanisms and opportunities for Cancer therapy	297
Exosome-based immunotherapy: a promising approach for cancer treatment	289
G-quadruplexes: a promising target for cancer therapy	286
The role of m6A, m5C and Ψ RNA modifications in cancer: Novel therapeutic opportunities	283
Lung cancer immunotherapy: progress, pitfalls, and promises	280
Wnt signaling in breast cancer: biological mechanisms, challenges and opportunities	278
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer	278
Cuproptosis: mechanisms and links with cancers	234
Mechanisms of vasculogenic mimicry in hypoxic tumor microenvironments	229
mRNA vaccine: a potential therapeutic strategy	222
Taking the Myc out of cancer: toward therapeutic strategies to directly inhibit c-Myc	221
mRNA therapeutics in cancer immunotherapy	208
Progressing nanotechnology to improve targeted cancer treatment: overcoming hurdles in its clinical implementation	197

Circular RNAs in body fluids as cancer biomarkers: the new frontier of liquid biopsies	196
m6A modification: recent advances, anticancer targeted drug discovery and beyond	194
Exosome biogenesis: machinery, regulation, and therapeutic implications in cancer	193
N6-methyladenosine-modified circIGF2BP3 inhibits CD8+ T-cell responses to facilitate tumor immune evasion by promoting the deubiquitination of PD-L1 in non-small cell lung cancer	193
Long noncoding RNAs: functions and mechanisms in colon cancer	192
Engineered exosomes as an in situ DC-primed vaccine to boost antitumor immunity in breast cancer	189
Long non-coding RNA NEAT1 promotes bone metastasis of prostate cancer through N6-methyladenosine	184
N6-methyladenosine-modified CircRNA-SORE sustains sorafenib resistance in hepatocellular carcinoma by regulating β-catenin signaling	184
Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments	183
METTL3/IGF2BP3 axis inhibits tumor immune surveillance by upregulating N6-methyladenosine modification of PD-L1 mRNA in breast cancer	174
Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer	168
Liquid biopsy in lung cancer: significance in diagnostics, prediction, and treatment monitoring	164
Cancer associated-fibroblast-derived exosomes in cancer progression	154
circCUL2 regulates gastric cancer malignant transformation and cisplatin resistance by modulating autophagy activation via miR-142-3p/ROCK2	152
Current applications and future perspective of CRISPR/Cas9 gene editing in cancer	151
Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy	150
Cross-talk of four types of RNA modification writers defines tumor microenvironment and pharmacogenomic landscape in colorectal cancer	149
Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing	147
EWSR1-induced circNEIL3 promotes glioma progression and exosome-mediated macrophage immunosuppressive polarization via stabilizing IGF2BP3	147
CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances	147
Epigenetic modulation of antitumor immunity for improved cancer immunotherapy	133
The circular RNA circ-ERBIN promotes growth and metastasis of colorectal cancer by miR-125a-5p and miR-138-5p/4EBP-1 mediated cap-independent HIF-1α translation	132
A novel protein encoded by circMAPK1 inhibits progression of gastric cancer by suppressing activation of MAPK signaling	132
Cancer cell-derived exosomal circUSP7 induces CD8+ T cell dysfunction and anti-PD1 resistance by regulating the miR-934/SHP2 axis in NSCLC	128
Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer	125
Advancements in nanoparticle-based treatment approaches for skin cancer therapy	120
Circular RNA hsa_circ_0004872 inhibits gastric cancer progression via the miR-224/Smad4/ADAR1 successive regulatory circuit	118
Proteolysis-targeting chimeras (PROTACs) in cancer therapy	118
Progress on pivotal role and application of exosome in lung cancer carcinogenesis, diagnosis, therapy and prognosis	117
Insights into N6-methyladenosine and programmed cell death in cancer	117
Application of the CRISPR/Cas9-based gene editing technique in basic research, diagnosis, and therapy of cancer	116
DDX3X: structure, physiologic functions and cancer	115
Circ3823 contributes to growth, metastasis and angiogenesis of colorectal cancer: involvement of miR-30c-5p/TCF7 axis	114
Targeting the RNA m6A modification for cancer immunotherapy	114
Expression profiles, biological functions and clinical significance of circRNAs in bladder cancer	111
LncRNA CRNDE attenuates chemoresistance in gastric cancer via SRSF6-regulated alternative splicing of PICALM	111
Targeting the tumor stroma for cancer therapy	108
Non-coding RNAs regulation of macrophage polarization in cancer	108
METTL14-mediated m6A modification of circORC5 suppresses gastric cancer progression by regulating miR-30c-2-3p/AKT1S1 axis	108
Liquid biopsy at the frontier of detection, prognosis and progression monitoring in colorectal cancer	107
Proteomics technologies for cancer liquid biopsies	102
circPARD3 drives malignant progression and chemoresistance of laryngeal squamous cell carcinoma by inhibiting autophagy through the PRKCI-Akt-mTOR pathway	102
M6A-mediated upregulation of circMDK promotes tumorigenesis and acts as a nanotherapeutic target in hepatocellular carcinoma	102
The FUS/circEZH2/KLF5/ feedback loop contributes to CXCR4-induced liver metastasis of breast cancer by enhancing epithelial-mesenchymal transition	102
Comprehensive landscape and future perspectives of circular RNAs in colorectal cancer	102
The role of lncRNAs and circRNAs in the PD-1/PD-L1 pathway in cancer immunotherapy	101
The hypoxia-driven crosstalk between tumor and tumor-associated macrophages: mechanisms and clinical treatment strategies	100
Demethylase ALKBH5 suppresses invasion of gastric cancer via PKMYT1 m6A modification	100
Clinical and immunological effects of mRNA vaccines in malignant diseases	99
Identification of tumor antigens and immune subtypes of pancreatic adenocarcinoma for mRNA vaccine development	99

Targeting CXCR2 inhibits the progression of lung cancer and promotes therapeutic effect of cisplatin	99
Two nanoformulations induce reactive oxygen species and immunogenetic cell death for synergistic chemo-immunotherapy eradicating colorectal cancer and hepatocellular carcinoma	98
Tumor-associated exosomes promote lung cancer metastasis through multiple mechanisms	97
Exosomal circLPAR1 functions in colorectal cancer diagnosis and tumorigenesis through suppressing BRD4 via METTL3–eIF3h interaction	97
Identification of tumor antigens and immune subtypes of cholangiocarcinoma for mRNA vaccine development	96
A signature of saliva-derived exosomal small RNAs as predicting biomarker for esophageal carcinoma: a multicenter prospective study	95
Exosome-derived circCCAR1 promotes CD8 + T-cell dysfunction and anti-PD1 resistance in hepatocellular carcinoma	95
Interaction of lncRNA MIR100HG with hnRNPA2B1 facilitates m6A-dependent stabilization of TCF7L2 mRNA and colorectal cancer progression	92
Molecular mechanisms of tumor resistance to radiotherapy	92
CircPTPRA blocks the recognition of RNA N6-methyladenosine through interacting with IGF2BP1 to suppress bladder cancer progression	91
Mesenchymal stem cell-derived exosomes in cancer therapy resistance: recent advances and therapeutic potential	91
The circular RNA circSPARC enhances the migration and proliferation of colorectal cancer by regulating the JAK/STAT pathway	90
Liquid biopsy: Exosomal microRNAs as novel diagnostic and prognostic biomarkers in cancer	90
Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers	89